|Bid||3.2300 x 2900|
|Ask||3.3000 x 800|
|Day's range||3.0700 - 3.3200|
|52-week range||2.4500 - 14.7300|
|Beta (5Y monthly)||-0.08|
|PE ratio (TTM)||N/A|
|Earnings date||06 Feb 2023 - 10 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.56|
The mean of analysts' price targets for Karyopharm Therapeutics (KPTI) points to a 96.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
KPTI earnings call for the period ending September 30, 2022.
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 19.64% and 3.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?